EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Leveraging [ 18 F ]F‐Piflufolastat PET for PBPK Prediction of Tissue Distribution and Therapy Optimization in Prostate Cancer

Suzanne van der Gaag iD, Mike J C Veerman iD, Habibe Yilmaz, Jan Amsu, Sebastian J V Pruijn, Daniela E Oprea-Lager iD, Matthijs C F Cysouw iD, Bernard H E Jansen iD, Maqsood M Yaqub iD, André N Vis iD, Harry Hendrikse iD, Imke H Bartelink iD

Clinical and Translational Science · 2026-05 · 19 (5)

DOI: 10.1111/cts.70583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 15.05.2026. Verfasst von Suzanne van der Gaag und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiopharmaceuticals, Heterocyclic Compounds, 1-Ring, Dipeptides. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate‐specific membrane antigen (PSMA) is overexpressed in over 90% of prostate cancer tumors, making it a strong target for imaging and therapy. The diagnostic tracer [ 18 F]F‐Piflufolastat provides high affinity and image quality, while the β‐emitter [ 177 Lu]Lu‐PSMA‐617 enables targeted treatment. Despite differences in radioactive half‐life, their shared PSMA‐binding and pharmacokinetic profiles suggest potential for translational pharmacokinetic modeling. We hypothesized that the published full‐body physiologically based pharmacokinetic (PBPK) model could be directly translated across the investigated PSMA ligands to predict tracer distribution within the same patient. A PBPK model was developed by rebuilding and modifying a published [ 68 Ga]Ga‐PSMA‐11/[ 177 Lu]Lu‐PSMA‐617 model to simulate [ 18 F]F‐Piflufolastat PK. Patient‐specific factors included tumor volume, PSMA receptor density, organ blood flow, and renal clearance. Verification used published data, dynamic positron emission tomography (PET) from eight patients, and static total‐body PET/computed tomography (CT) at 2 h from five patients. Extrapolation to [ 177 Lu]Lu‐PSMA‐617, using fitted receptor density, was evaluated against 24‐h and 7‐day Single‐Photon Emission Computed Tomography (SPECT) data from two patients using mean prediction error (PE). The model accurately predicted [ 18 F]F‐Piflufolastat tumor uptake (median PE −3.44% (IQR −3.79 to −3.17) and −3.53% (IQR −3.78 to −3.00) in internal and external cohorts) and showed consistency with 7‐day [ 177 Lu]Lu‐PSMA‐617 SPECT observations. However, predictions for other organs were variable (median PE ranging between −89.7 and 144), indicating limitations of a one‐to‐one molecular translational approach. These findings demonstrate that PBPK modeling can capture key determinants of PSMA tracer distribution, and link [ 18 F]F‐Piflufolastat imaging to [ 177 Lu]Lu‐PSMA‐617 predictions. However, improved representation of systemic and organ‐level kinetics is required. Future work should explore a limited PBPK approach, focusing on accurate blood kinetics and organ‐specific modeling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsRadiopharmaceuticalsHeterocyclic Compounds, 1-RingDipeptidesMaleHumansTissue DistributionAntigens, SurfacePositron Emission Tomography Computed TomographyPositron-Emission TomographyModels, BiologicalGlutamate Carboxypeptidase IIFluorine RadioisotopesLutetiumRadioisotopesAgedProstate-Specific Antigen

Stichwörter der Autor:innen

PSMAimagingmodelingprostate cancertherapy

Substanzen

RadiopharmaceuticalsHeterocyclic Compounds, 1-RingAntigens, SurfaceDipeptidesFOLH1 protein, humanGlutamate Carboxypeptidase IIFluorine RadioisotopesLutetiumPSMA-617Radioisotopes

Autor:innen und Institutionen

  • Department of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.
  • Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Urology, Prostate Cancer Network Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Department of Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, GD, the Netherlands.

ORCID-Profile: Suzanne van der Gaag, Mike J C Veerman, Daniela E Oprea-Lager, Matthijs C F Cysouw, Bernard H E Jansen, Maqsood M Yaqub, André N Vis, Harry Hendrikse, Imke H Bartelink

Zitieren

APA

van der Gaag, S., Veerman, M. J. C., Yilmaz, H., Amsu, J., Pruijn, S. J. V., Oprea-Lager, D. E., Cysouw, M. C. F., Jansen, B. H. E., Yaqub, M. M., Vis, A. N., Hendrikse, H., & Bartelink, I. H. (2026). Leveraging [ 18 F ]F‐Piflufolastat PET for PBPK Prediction of Tissue Distribution and Therapy Optimization in Prostate Cancer. Clinical and Translational Science, 19(5). https://doi.org/10.1111/cts.70583

Vancouver

van der Gaag S, Veerman MJC, Yilmaz H, Amsu J, Pruijn SJV, Oprea-Lager DE, et al. Leveraging [ 18 F ]F‐Piflufolastat PET for PBPK Prediction of Tissue Distribution and Therapy Optimization in Prostate Cancer. Clinical and Translational Science. 2026;19(5). doi:10.1111/cts.70583

BibTeX
@article{vanderGaag2026,
  author = {van der Gaag, Suzanne and Veerman, Mike J C and Yilmaz, Habibe and Amsu, Jan and Pruijn, Sebastian J V and Oprea-Lager, Daniela E and Cysouw, Matthijs C F and Jansen, Bernard H E and Yaqub, Maqsood M and Vis, André N and Hendrikse, Harry and Bartelink, Imke H},
  title = {Leveraging [ 18 F ]F‐Piflufolastat PET for PBPK Prediction of Tissue Distribution and Therapy Optimization in Prostate Cancer},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {5},
  doi = {10.1111/cts.70583}
}
Kostenlos starten →